INS and Obesity: In addition to TI improvement in glycemic control, our studies reveal other aspects of IRPA pharmacology with potential to provide additional benefits compared to insulin, including less body weight gain and atherosclerotic lesion reduction, both of which are highly desirable for diabetic patients with comorbidities of obesity and / or dyslipidemia.